Epidemiological use of rectal proliferation measures

Area of Science:

• Gastroenterology
• Oncology
• Biomarker Research

Background:

• Rectal mucosal proliferation measures are valuable in research but their large-scale epidemiological utility is uncertain.
• Assessing proliferation markers is crucial for understanding adenoma recurrence and colorectal cancer development.

Purpose of the Study:

• To evaluate the suitability of bromodeoxyuridine (BrdUrd) and proliferating cell nuclear antigen (PCNA) labeling indices (LIs) for large-scale studies.
• To determine the feasibility of rectal mucosal biopsy and biomarker analysis in a multicenter clinical trial setting.

Main Methods:

• Rectal mucosal biopsies were collected from patients undergoing colonoscopy in a multicenter trial.
• Proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdUrd) labeling indices (LIs) were computed.
• Specimen preparation success and number of scorable crypts were assessed for both markers.

Main Results:

• Patient consent for biopsy was high (>90%); PCNA specimen preparation was acceptable with a mean of 12.99 scorable crypts.
• BrdUrd labeling showed lower success rates with fewer scorable crypts.
• PCNA LI (4.1) was modestly higher than BrdUrd LI (3.7) (P=0.03), with a rank correlation of 0.38.

Conclusions:

• Proliferating cell nuclear antigen (PCNA) labeling is a feasible method for measuring rectal mucosal proliferation in large endoscopy-based studies.
• Bromodeoxyuridine (BrdUrd) labeling presents greater challenges for specimen preparation and analysis in this context.
• Further research is needed to understand the relationship between PCNA and BrdUrd labeling indices.